StockData
Exagen Inc. logo

Exagen Inc. (XGN) stock

XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.76−0.01 (-0.27%)

Close on Nov 17, 2026Market cap $91.09MP/E –Yield –

Exagen price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Exagen's price to sales ratio was 1.7× on Nov 11, 2026, against 2.8× a year earlier. Over the last 5 years it ranged from 0.4× to 4.4×, with a median of 1.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.7×−0.4
2025Dec 31, 20252.2×+0.9
2024Dec 31, 20241.3×+0.6
2023Dec 29, 20230.7×−0.2
2022Dec 30, 20220.9×−3.0
2021Dec 31, 20213.9×−0.3
2020Dec 31, 20204.2×−3.8
2019Dec 31, 20198.0×–

More Exagen figures

See a number that looks wrong?